ClinicalTrials.gg
Status unknownNCT03556800Updated Apr 27, 2022

Study to Investigate the Pharmacokinetics & Safety Following One Application of 3 Different Doses 0.5,0.75,& 1.25 gm,a Transdermal Estradiol Cream (VML-0203), in Comparison to a Single Dose of EstroGel 1.25 gm to Healthy Post-menopausal Women.

A Phase 1 interventional study of Estrogel in Menopause, sponsored by Viramal Limited. Status unknown at 1 site in United Kingdom. Open to female participants aged 30 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-04-27.

Sponsored by Viramal Limited · Phase 1, Interventional, and Supportive care

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Randomized
Ages
30 Years and older
Sex
Female
01

Study summary

This study is a Phase I, Randomized, Open-Label, Single Center, Cross-over Study to Investigate the Pharmacokinetics and Safety following a Single Application of Three Different Doses 0.5 gm (0.5 mg estradiol), 0.75 gm (0.75 mg estradiol) and 1.25 gm (1.25 mg estradiol), a Transdermal Estradiol Cream (VML-0203), in comparison to a single dose of EstroGelTM 1.25 gm (1 unit/0.75 mg of estradiol) to healthy post-menopausal women.

02

Conditions studied

  • Menopause

Keywords

  • Hypoestrogenism
  • Menopausal hormone therapy
03

In context

Lead sponsor

Viramal Limited is the lead sponsor of 3 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Female
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy (surgical or natural) female defined as:
  • No menstrual period within the past year before study entry.
  • Serum estradiol levels between 0-20 pg/ml.
  • FSH levels greater than 25.8 mIU/ml.
  • Greater than 45 years of age or if surgical menopausal, > 30 yrs. of age.
  • Have a (BMI) between 18 and 30 kg/m2. Have had a normal PAP smear test result in line with the following guidelines:

    • aged 30 to 49 - within the last 3 years
    • aged 50 to 65 - within the last 5 years

Exclusion criteria

Exclusion Criteria:

  • Is pregnant (urine pregnancy test at screening) or lactating.
  • Has evidence of drug or alcohol abuse.
  • Have used hormonal replacement or vaginal hormonal therapy within the past three months before study entry.
  • Have used estrogen pellet therapy or progestin injectable drug therapy within the past three months before study entry.
  • Has to HRT use, including: unexplained vaginal bleeding, liver disease, breast or endometrial cancer, venous thromboembolic events.
  • Any subjects with an obvious presence of skin conditions, excessive hair at the application sites (no shaving), scar tissue, tattoo, or coloration that would interfere with application of IMP, skin assessment, or reactions to drug.
  • Presence of open sores at the application sites.
  • Any subjects with a history of significant skin disorder.
  • Smoker.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 1
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    0.5 gm of EstroCream (VML-0203)

    Drug: Estrogel

  • Experimental
    0.75 gm of EstroCream (VML-0203)

    Drug: Estrogel

  • Experimental
    1.25 gm of EstroCream (VML-0203)

    Drug: Estrogel

  • Active comparator
    1.25 EstroGel

    Drug: Estrogel

Interventions

  • Each subject will receive the following IMPs in accordance with the randomisation code: * Test IMP: a single-dose of 0.5g, 0.75g and 1.25g VML-0203 cream * Reference IMP: a single-dose of 1.25g EstroGel

    Also known as: EstroCream

06

What researchers measure

Primary outcomes

  1. To compare the bio-availability of estradiol and estrone.

    Blood samples will be analysed.

    Time frame: 4 weeks

Secondary outcomes

  1. To provide general safety information for VML-0203.

    Application site inspections will be assessed.

    Time frame: 4 weeks

07

Study locations

1 of 1 sites recruiting
  • Simbec Research Ltd
    Merthyr Tydfil, Wales CF48 4DR, United Kingdom
    Recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started May 2018 (actual). Primary completion is estimated for Jun 2022, 49 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 1, 2018
First posted
Jun 14, 2018
StartActual
May 22, 2018
Primary completionEst.
Jun 30, 2022
CompletionEst.
Jun 30, 2022
Last update
Apr 27, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03556800
Lead sponsor
Viramal Limited
Collaborators
Simbec Research
Responsible party
Sponsor
First posted
Jun 14, 2018
Start date
May 22, 2018
Primary completion
Jun 30, 2022 (estimated)
Completion
Jun 30, 2022 (estimated)
Last update
Apr 27, 2022

Study contacts

Dr Simona Fiore, MD
Contact
Sfiore@viramal.com
020 7495 3052
Dr Simona Fiore, MD
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Estradiol

Start the discussion